Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
- New data support potential use of plozasiran without dose adjustment in patients with moderate-to-severe renal or moderate hepatic impairment
- Case report suggests that preconception exposure to plozasiran may be associated with sustained lowering of fasting triglyceride levels throughout the term of a pregnancy
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented new positive clinical data for plozasiran supporting its use in patients with moderate-to-severe renal impairment or moderate hepatic impairment without the need for dose adjustment, and a case report suggesting that preconception exposure to plozasiran may be associated with sustained lowering of fasting triglyceride (TG) levels through the term of a pregnancy. The data were presented in two oral presentations at the 94th European Atherosclerosis Society (EAS) Congress, taking place in Athens, Greece from May 24-27.
“Patients living with extremely high triglycerides often suffer from significant comorbidities. Today’s data represent an important step in bridging the gap between patient needs and scientific innovation,” said Jennifer Hellawell, MD, board-certified cardiologist and Vice President of Clinical Development at Arrowhead Pharmaceuticals. “As a physician at heart, I’m proud to be part of the team advancing next-generation therapies for this underserved community. We’re excited to have better characterized the PK and PD of plozasiran in this potentially broader patient population. These data bring us closer to delivering meaningful impact for patients.”
